Cisplatin and radiation in the treatment of tumors of the central nervous system: pharmacological considerations and results of early studies

• Published in: International journal of radiation oncology, biology, physics Vol. 28; no. 2; p. 531
• Main Authors: Stewart, D J, Molepo, J M, Eapen, L, Montpetit, V A, Goel, R, Wong, P T, Popovic, P, Taylor, K D, Raaphorst, G P
• Format: Journal Article
• Language: English
• Published: United States 15-01-1994
• Subjects: Brain Neoplasms - drug therapy; Brain Neoplasms - metabolism; Brain Neoplasms - radiotherapy; Cisplatin - pharmacokinetics; Cisplatin - therapeutic use; Combined Modality Therapy; Humans; Platinum - pharmacokinetics
• ISSN: 0360-3016
• DOI: 10.1016/0360-3016(94)90082-5

To review the human central nervous system pharmacology of cisplatin, factors that affect cisplatin uptake in tumors, and use alone and with radiation for the treatment of primary brain tumors.
The authors review their own prior published and unpublished experience and data published by other groups on the above issues.
Cisplatin is one of the most active chemotherapy drugs available for the treatment of solid tumors. It is synergistic with several other agents, including radiation. While it attains only low concentrations in the normal central nervous system, concentrations and plasma-tissue transfer constants for human intracerebral tumors are comparable to those in extracerebral tumors. Tumor type appears to be a more important determinant of platinum concentration than is tumor location, and gliomas do achieve lower concentrations than do other intracerebral or extracerebral tumors. Several other factors have also been identified that correlate with concentrations of cisplatin achieved in human tumors. While cisplatin alone and in combination with other drugs does have some degree of efficacy against primary brain tumors, combining it with cranial irradiation has generally not resulted in any substantial improvement in outcome to date, although some individual studies have been somewhat encouraging. New approaches are currently under investigation.
Human pharmacology studies provide a rationale for use of cisplatin in the treatment of human brain tumors, and human and in vitro studies suggest some manipulations that might potentially further augment tumor platinum concentrations. While clinical studies suggest that cisplatin combinations may be of some value vs. human primary brain tumors and brain metastases, and while in vitro studies suggest that cisplatin potentiates radiation efficacy, no combination of cisplatin plus radiation yet tested has appeared to be superior to radiation alone.